Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

756
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
756
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

316
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
316
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

640
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
640
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.1K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

311
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
311
Drug Therapy01:28

Drug Therapy

391
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
391

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2025
Same author

Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction.

Pharmacotherapy·2020
Same author

Association between Use of Methadone, Other Central Nervous System Depressants, and QTc Interval-Prolonging Medications and Risk of Mortality in a Large Cohort of Women Living with or at Risk for Human Immunodeficiency Virus Infection.

Pharmacotherapy·2019
Same author

Enhancing our understanding of perinatal depression.

CNS spectrums·2015
Same author

Detection and treatment rates for perinatal depression in a state Medicaid population.

CNS spectrums·2014
Same author

A pilot study evaluating genetic and environmental factors for postpartum depression.

Innovations in clinical neuroscience·2013
Same journal

Clinical Pharmacokinetics and Pharmacodynamics of the IL-1 Receptor Antagonist Anakinra: A Systematic Review.

Clinical pharmacokinetics·2026
Same journal

Physiologically Based Pharmacokinetic (PBPK) Modeling of Antidepressants: A Scoping Review of Existing Models, Applications, and Software Tools.

Clinical pharmacokinetics·2026
Same journal

Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.

Clinical pharmacokinetics·2026
Same journal

Partial Area Under the Curve: A Revelatory Story in Pharmacokinetics.

Clinical pharmacokinetics·2026
Same journal

Informing Sampling Design for Lung Distribution Studies Using a Pulmonary Population Minimal PBPK Model.

Clinical pharmacokinetics·2026
Same journal

Revisited Pharmacokinetic Profiles of Methylprednisolone in Plasma and Urine After Single and Multiple Oral Administrations: Relevance in Sports Drug Testing.

Clinical pharmacokinetics·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

The Tail Suspension Test
10:17

The Tail Suspension Test

Published on: January 28, 2012

84.0K

Drug Interactions with Lithium: An Update.

Patrick R Finley1

  • 1School of Pharmacy, University of California at San Francisco, 3333 California Street, Box 0613, San Francisco, CA, 94143-0613, USA. finleyp@pharmacy.ucsf.edu.

Clinical Pharmacokinetics
|March 4, 2016
PubMed
Summary
This summary is machine-generated.

This review updates evidence on lithium drug interactions, focusing on pharmacokinetic changes over the last 20 years. Understanding these interactions is crucial for managing bipolar disorder safely and effectively.

More Related Videos

A Protocol for Safe Lithiation Reactions Using Organolithium Reagents
09:45

A Protocol for Safe Lithiation Reactions Using Organolithium Reagents

Published on: November 12, 2016

32.3K
Solid-state Graft Copolymer Electrolytes for Lithium Battery Applications
05:33

Solid-state Graft Copolymer Electrolytes for Lithium Battery Applications

Published on: August 12, 2013

22.4K

Related Experiment Videos

Last Updated: Mar 24, 2026

The Tail Suspension Test
10:17

The Tail Suspension Test

Published on: January 28, 2012

84.0K
A Protocol for Safe Lithiation Reactions Using Organolithium Reagents
09:45

A Protocol for Safe Lithiation Reactions Using Organolithium Reagents

Published on: November 12, 2016

32.3K
Solid-state Graft Copolymer Electrolytes for Lithium Battery Applications
05:33

Solid-state Graft Copolymer Electrolytes for Lithium Battery Applications

Published on: August 12, 2013

22.4K

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Pharmacy

Background:

  • Lithium is a first-line treatment for bipolar disorder with a narrow therapeutic index.
  • Altered lithium plasma concentrations can lead to significant clinical issues.
  • Existing evidence on lithium drug interactions is largely outdated, necessitating an update.

Purpose of the Study:

  • To review and update evidence on potential drug interactions with lithium.
  • To focus on pharmacokinetic insights from the past two decades.
  • To discuss the clinical relevance of these interactions.

Main Methods:

  • Literature review of studies on lithium drug interactions.
  • Focus on pharmacokinetic data published within the last 20 years.
  • Analysis of clinical relevance and implications of identified interactions.

Main Results:

  • Identified several drug classes with potential for lithium interaction.
  • Highlighted pharmacokinetic mechanisms underlying these interactions.
  • Discussed the clinical significance of updated interaction data.

Conclusions:

  • An updated understanding of lithium drug interactions is essential for safe patient management.
  • Pharmacokinetic changes are key to understanding current lithium-drug interactions.
  • This review provides current evidence for clinicians managing lithium therapy.